GRF:BME
Grifols SA Class A
€9.54
arrow_downward
-0.60%(-0.058) 1D
Oct 2, 2:17:10 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GRF...
Open
€9.57
High
€9.71
Low
€9.48
Mkt. cap
5.77B
Avg. vol.
1.13M
Volume
428.77K
Dividend
2.44%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
14.35
52-wk high
€12.87
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
Open
€9.57
High
€9.71
Low
€9.48
Mkt. cap
5.77B
Avg. vol.
1.13M
Volume
428.77K
Dividend
2.44%
Quarterly dividend
€0.06
Ex-dividend date
Jun 30, 2026
P/E ratio
14.35
52-wk high
€12.87
52-wk low
€8.43
EPS
€0.67
Shares outstanding
426.13M
No. of employees
25K
News stories
From web sources and news partners
FXEmpire
·
9 minutes ago
S&P500: Futures Rise as Oil Retreats Before Payrolls
24/7 Wall St.
·
1 hour ago
IWM Has Trailed the S&P 500 for a Decade While Carrying More Risk: The Small-Cap Premium That Never Fully Arrived
Barron's
·
1 hour ago
S&P 500 Futures Climb in Premarket Trading; Seagate Technology, Nike Lag
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30.
Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA Class A